Yüklüyor......
An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors
EGFR is an oncogene with a high frequency of activating mutations in nonsmall cell lung cancer (NSCLC). EGFR inhibitors have been FDA-approved for NSCLC and have shown efficacy in patients with certain EGFR mutations. However, only 9% to 26% of these patients achieve objective responses. In our stud...
Kaydedildi:
| Yayımlandı: | Int J Cancer |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7880578/ https://ncbi.nlm.nih.gov/pubmed/32406930 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.33053 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|